Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3)

Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 development for the treatment of type 2 diabetes (T2D). In this 56-week, open-label study, 813 adults with T2D inadequately controlled on 1 to 2 oral antidiabetic drugs (OADs; metformin, sulfonylurea, thiazolidinediones) were randomized 1:1 to once-weekly semaglutide 1.0 mg or once-weekly exenatide extended release (ER) 2.0 mg. Primary endpoint was change in glycated hemoglobin (HbA1c) from baseline to Week 56.